New SOP to enhance transparency and quality of Real-World Data

ERDERA JTC2026

A new Standard Operating Procedure (SOP) titled “Validation, Publication, and Maintenance of Real-World Data Sources and Studies in the HMA-EMA RWD Catalogues” (SOP/TDA/3543) has been published by the European Medicines Agency (EMA). This SOP outlines the systematic approach adopted by the EMA for ensuring the accuracy, completeness, and transparency of data included in the HMA-EMA real-world data catalogues.

The SOP provides clear guidance for both EMA staff and catalogue users on the processes of data validation, publication, and ongoing maintenance. It ensures that submitted data sources and studies are not only relevant and non-duplicative, but also supported by comprehensive and standardised metadata.

Notably, this new procedure will help strengthen the robustness of the real-world evidence ecosystem, ultimately enhancing its credibility and accountability in regulatory decision-making. Learn more from the document.

News & Updates

You might also be interested in

Advancement of Treatments for Rare Diseases

Advancement of Treatments for Rare Diseases

The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.
Molecular therapy

Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation

Outside traditional drug development pathways, clinicians and scientists face the challenge of systematically evaluating whether individual patients with severe ultrarare diseases might be eligible for and potentially benefit from individualized mutation-specific RNA therapies.
P065130-414294

Joining the Dots: EURORDIS’ role in ERDERA and the reshaping of rare disease research

EURORDIS champions patient-centred innovation in rare disease research
ERDERA JTC2026

ERDERA announces first Joint Transnational Call 2025 portfolio of preclinical therapy projects for rare diseases

Eighteen international pre clinical therapy projects selected under ERDERA’s first Joint Transnational Call will accelerate treatment options for people living with rare diseases across Europe and beyond

ERDERA's

search form